Trial Profile

An Open-Label, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 29 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ALX-001 (Primary)
Indications Alzheimer's disease
Focus Adverse reactions; Pharmacokinetics
Sponsors Allyx Therapeutics

Most Recent Events

30 Oct 2023 Results presented in the Allyx Therapeutics Media Release.
30 Oct 2023 According to an Allyx Therapeutics media release, data from this trial were presented at the 16th Clinical Trials on Alzheimer's Disease (CTAD) meeting 2023.
19 Oct 2023 According to an Allyx Therapeutics media release, this trial was conducted at Yale University and supported with grant funding from the National Institutes of Health and the Alzheimer's Association.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com